US National Cancer Institute to test seven novel cancer drugs from Clavis Pharma
29 May 2007 -
Clavis Pharma announced that the US National Cancer Institute has accepted seven new compounds from the company for testing under its Developmental Therapeutics Program. The drug candidates, which are structurally novel analogues of several cancer drugs, have been synthesized by applying Clavis Pharma's proprietary Lipid Vector Technology. The drug candidates will be screened in a well-established
cell line test panel (NCI-60) against a variety of cancer types. Positive pre-clinical results from the NCI screening program, will constitute important pre-clinical documentation for these products and potentially contribute to the broadening of Clavis Pharma's oncology pipeline. Previously Clavis' two most advanced drug candidates, Elacyt(TM) and CP.4126, have also undergone similar NCI screening.
Top
Contact
Print version
PDF version
Send article
RSS feed
